According to Professor Colin Pouton's Lipid Formulation Classification System, when you incorporate an oil phase and and an water-insoluble surfactant, you are expected to get a Type II SEDDS. I am recently developing such system employing Labrafac™ lipophile WL 1349 as oil and Labrafil® M 1944 CS as surfactant. The drug is Gambogic Acid which has extremely low aqueous solubility. I discovered that when 1349 is used alone, the precentage of drug dissolved in the aqueous phase after in vitro lipolysis is approximately 40%, but when combined with 1944（the ratio between 1349:1944 is 50:50）, this number dropped sharply, to approx. 7%. I also find that the higher the proportion of 1944 is, the lower the precentage of drug dissolved in the aqueous phase is. I wonder what the virtue in using 1944 in SEDDS formulation is. I cannot find such papers dealing with this question. Thanks a lot!
Lipid-based medication carriers are believed to impact bioavailability by increasing drug solubilization in the gastrointestinal system. The purpose of the study was to look at the digestibility of lipid formulations in simulated gastro intestinal medium. Fenofibrate was formulated as an excipient in Type II, IIIA, IIIB, and IV self-emulsifying/microemulsifying lipid delivery systems (SEDDS and SMEDDS designed for oral administration) with different medium-chain glyceride components, non-ionic surfactants, and cosolvents. Soybean oil was solely utilised as an example of a long-chain triglyceride to compare formulation effects with their equivalents.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs